JP2011098965A5 - - Google Patents

Download PDF

Info

Publication number
JP2011098965A5
JP2011098965A5 JP2010250815A JP2010250815A JP2011098965A5 JP 2011098965 A5 JP2011098965 A5 JP 2011098965A5 JP 2010250815 A JP2010250815 A JP 2010250815A JP 2010250815 A JP2010250815 A JP 2010250815A JP 2011098965 A5 JP2011098965 A5 JP 2011098965A5
Authority
JP
Japan
Prior art keywords
weight percent
composition
pharmaceutically acceptable
spherical particles
iii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010250815A
Other languages
English (en)
Japanese (ja)
Other versions
JP5866116B2 (ja
JP2011098965A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011098965A publication Critical patent/JP2011098965A/ja
Publication of JP2011098965A5 publication Critical patent/JP2011098965A5/ja
Application granted granted Critical
Publication of JP5866116B2 publication Critical patent/JP5866116B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010250815A 2009-11-09 2010-11-09 嘔吐および下痢などの状態を解消または軽減するためのコーティングされた薬物球状体およびその用途 Active JP5866116B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25938709P 2009-11-09 2009-11-09
US61/259,387 2009-11-09

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015013685A Division JP5982020B2 (ja) 2009-11-09 2015-01-27 嘔吐および下痢などの状態を解消または軽減するためのコーティングされた薬物球状体およびその用途

Publications (3)

Publication Number Publication Date
JP2011098965A JP2011098965A (ja) 2011-05-19
JP2011098965A5 true JP2011098965A5 (cg-RX-API-DMAC7.html) 2013-12-19
JP5866116B2 JP5866116B2 (ja) 2016-02-17

Family

ID=43828063

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010250815A Active JP5866116B2 (ja) 2009-11-09 2010-11-09 嘔吐および下痢などの状態を解消または軽減するためのコーティングされた薬物球状体およびその用途
JP2015013685A Active JP5982020B2 (ja) 2009-11-09 2015-01-27 嘔吐および下痢などの状態を解消または軽減するためのコーティングされた薬物球状体およびその用途
JP2016025515A Pending JP2016094478A (ja) 2009-11-09 2016-02-15 嘔吐および下痢などの状態を解消または軽減するためのコーティングされた薬物球状体およびその用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015013685A Active JP5982020B2 (ja) 2009-11-09 2015-01-27 嘔吐および下痢などの状態を解消または軽減するためのコーティングされた薬物球状体およびその用途
JP2016025515A Pending JP2016094478A (ja) 2009-11-09 2016-02-15 嘔吐および下痢などの状態を解消または軽減するためのコーティングされた薬物球状体およびその用途

Country Status (11)

Country Link
US (2) US8524281B2 (cg-RX-API-DMAC7.html)
EP (1) EP2498751B1 (cg-RX-API-DMAC7.html)
JP (3) JP5866116B2 (cg-RX-API-DMAC7.html)
CN (4) CN102724962B (cg-RX-API-DMAC7.html)
AR (1) AR078951A1 (cg-RX-API-DMAC7.html)
AU (1) AU2010315362B2 (cg-RX-API-DMAC7.html)
CA (1) CA2780332C (cg-RX-API-DMAC7.html)
ES (1) ES2729677T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ599762A (cg-RX-API-DMAC7.html)
TW (1) TWI429437B (cg-RX-API-DMAC7.html)
WO (1) WO2011056741A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ556673A (en) 2005-02-03 2010-03-26 Gen Hospital Corp Method for treating gefitinib and/or erlotinib resistant cancer with an EGFR inhibitor
EP3488866A1 (en) 2005-11-04 2019-05-29 Wyeth LLC Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
ES2531322T3 (es) 2008-06-17 2015-03-13 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
EP3175853B1 (en) 2008-08-04 2023-11-01 Wyeth LLC Antineoplastic combinations of neratinib and capecitabine
PT3000467T (pt) 2009-04-06 2023-03-30 Wyeth Llc Regime de tratamento utilizando neratinib para o cancro de mama
EP2498751B1 (en) 2009-11-09 2019-04-03 Wyeth LLC Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
CN102675287A (zh) * 2011-03-11 2012-09-19 江苏恒瑞医药股份有限公司 (e)-n-[4-[[3-氯-4-(2-吡啶基甲氧基)苯基]氨基]-3-氰基-7-乙氧基-6-喹啉基]-3-[(2r)-1-甲基吡咯烷-2-基]丙-2-烯酰胺的可药用的盐、其制备方法及其在医药上的应用
US9301957B2 (en) * 2011-11-14 2016-04-05 Novartis Ag Immediate release 4-methyl-3-4[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-YL)-3-(trifluoromethyl)phenyl] benzamide formulation
WO2025213381A1 (en) * 2024-04-10 2025-10-16 Hangzhou Jitai Pharmaceutical Technology Co., Ltd Neratinib-cyclodextrin composition and method for preparing same

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54119021A (en) * 1978-03-06 1979-09-14 Nippon Kayaku Co Ltd Carcinostatic agent
JPH0436237A (ja) * 1990-06-01 1992-02-06 Taiho Yakuhin Kogyo Kk 抗腫瘍性複合製剤
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6288082B1 (en) 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
US6384051B1 (en) 2000-03-13 2002-05-07 American Cyanamid Company Method of treating or inhibiting colonic polyps
US6821988B2 (en) 2001-11-27 2004-11-23 Wyeth Holdings Corporation 3-cyanoquinolines as inhibitors of EGF-R and HER2 kinases
US20040122048A1 (en) * 2002-10-11 2004-06-24 Wyeth Holdings Corporation Stabilized pharmaceutical composition containing basic excipients
CL2004000016A1 (es) 2003-01-21 2005-04-15 Wyeth Corp Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina.
US20050025825A1 (en) * 2003-07-31 2005-02-03 Xanodyne Pharmacal, Inc. Tranexamic acid formulations with reduced adverse effects
KR20060054412A (ko) 2003-08-01 2006-05-22 와이어쓰 홀딩스 코포레이션 암 치료 및 억제용 표피 성장인자 수용체 키나제 억제제와세포독성제의 배합물 용도
US7399865B2 (en) 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US20050142192A1 (en) 2003-10-15 2005-06-30 Wyeth Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives
EP2439284B1 (en) 2004-03-31 2019-05-08 The General Hospital Corporation Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
WO2006093353A1 (ja) * 2005-03-03 2006-09-08 Takeda Pharmaceutical Company Limited 放出制御組成物
US7767668B2 (en) 2005-04-28 2010-08-03 Wyeth Llc Micronized tanaproget, compositions, and methods of preparing the same
WO2006127205A2 (en) * 2005-05-25 2006-11-30 Wyeth Methods of preparing 3-cyano-quinolines and intermediates made thereby
TW200740427A (en) 2005-07-15 2007-11-01 Wyeth Corp Highly bioavailable oral delayed release dosage forms of O-desmethylvenlafaxine succinate
CN101300029A (zh) * 2005-11-04 2008-11-05 惠氏公司 mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
EP3488866A1 (en) * 2005-11-04 2019-05-29 Wyeth LLC Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
CA2629249C (en) * 2005-11-11 2015-05-05 Boehringer Ingelheim International Gmbh Combination treatment of cancer comprising egfr/her2 inhibitors
WO2007075794A2 (en) * 2005-12-22 2007-07-05 Wyeth Oral formulations comprising tigecycline
TW200806282A (en) * 2006-05-05 2008-02-01 Wyeth Corp Solid dosage formulations
EP2117518A2 (en) 2007-01-12 2009-11-18 Wyeth a Corporation of the State of Delaware Tablet-in-tablet compositions
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
AU2008325219A1 (en) 2007-11-05 2009-05-14 Puretech Ventures Methods, kits, and compositions for administering pharmaceutical compounds
CN101185633A (zh) * 2007-12-14 2008-05-28 山东蓝金生物工程有限公司 一种治疗实体肿瘤的尼拉替尼缓释植入剂
BRPI0906473A8 (pt) * 2008-01-04 2016-02-10 Intellikine Inc Certas entidades químicas, composições e métodos
WO2009146034A2 (en) * 2008-03-31 2009-12-03 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
TWI519322B (zh) * 2008-04-15 2016-02-01 愛戴爾製藥股份有限公司 包含弱鹼性藥物及控制釋放劑型之組合物
ES2531322T3 (es) 2008-06-17 2015-03-13 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
EP3175853B1 (en) 2008-08-04 2023-11-01 Wyeth LLC Antineoplastic combinations of neratinib and capecitabine
WO2010048477A2 (en) 2008-10-24 2010-04-29 Wyeth Llc Improved process for preparation of coupled products from 4-amino-3-cyanoquinolines using stabilized intermediates
PT3000467T (pt) 2009-04-06 2023-03-30 Wyeth Llc Regime de tratamento utilizando neratinib para o cancro de mama
CA2766067A1 (en) 2009-07-02 2011-01-06 Wyeth Llc 3-cyanoquinoline tablet formulations and uses thereof
KR20110007985A (ko) 2009-07-17 2011-01-25 한올바이오파마주식회사 N,n―디메틸 이미도디카르본이미딕 디아미드의 부틸산염, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이를 포함하는 복합제제
KR20110007984A (ko) 2009-07-17 2011-01-25 한올바이오파마주식회사 N,n―디메틸 이미도디카르본이미딕 디아미드의 프로피온산염, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이를 포함하는 복합제제
WO2011025267A2 (ko) 2009-08-25 2011-03-03 한올바이오파마주식회사 메트포르민 메탄설폰산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
WO2011025271A2 (ko) 2009-08-25 2011-03-03 한올바이오파마주식회사 메트포르민 아스코르브산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
KR101190953B1 (ko) 2009-08-25 2012-10-12 한올바이오파마주식회사 메트포르민 타우린염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
EP2498751B1 (en) 2009-11-09 2019-04-03 Wyeth LLC Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
EP3566697B1 (en) 2009-11-09 2024-09-11 Wyeth LLC Tablet formulations of neratinib maleate
EP2510121A1 (en) 2009-12-11 2012-10-17 Wyeth LLC Phosphatidylinositol-3-kinase pathway biomarkers
JP6126382B2 (ja) 2010-01-13 2017-05-10 ワイス・エルエルシー 腫瘍を正確に識別し、かつPAN‐ErbB阻害剤に対する薬物応答を予測するPTENタンパク質発現におけるカットポイント

Similar Documents

Publication Publication Date Title
NZ599762A (en) Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
RU2370495C2 (ru) Дополнительные гетероциклические соединения и их применение в качестве антагонистов метаботропного глутаматного рецептора
MX2022002952A (es) Formulaciones de liberacion modificada de 2-[3-[4-amino-3-(2-fluor o-4-fenoxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbo nil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enenitrilo.
CN102933573B (zh) 包含酰胺衍生物或其可药用盐的药物组合物
RU2008148547A (ru) Фармацевтические композиции, включающие дулоксетина гидрохлорид с замедленным высвобождением
CN105106203B (zh) 富马酸沃诺拉赞的药物组合物及其制备方法
JP2007511510A (ja) 持続放出性ベンラファキシン製剤
TW200635618A (en) Solid dosage form comprising proton pump inhibitor and suspension made thereof
CN1301534A (zh) 稳定的缓释口服给药组合物
US9770437B2 (en) Compositions of eltrombopag
NO20081325L (no) Nye doseringsformuleringer
IE880901L (en) A crivastine containing composition
NO330144B1 (no) Gastrobeskyttede omeprazolmikrogranuler, fremgangsmate for a oppna slike og farmasoytiske preparater
WO2008067399A3 (en) Controlled-release multi-layer formulation of piperazine-piperidine antagonists and agonists of the 5-th1a receptor having enhanced intestinal dissolution
JPWO2017018473A1 (ja) 錠剤
RU2011152105A (ru) Составы таблеток 3-цианохинолина и их применение
RU2014129508A (ru) Новая комбинация
RU2007148195A (ru) Пероральные дозированные формы о-десметилвенлафаксин сукцината повышенной биодоступности с отсроченным высвобождением
WO2012150412A1 (fr) Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent
TW201707702A (zh) 一種含有喹啉衍生物或其鹽的醫藥組成物
CA2471566A1 (en) Combination of mtp inhibitors or apob-secretion inhibitors with fibrates for use as pharmaceuticals
EA200600675A1 (ru) Гранулы, содержащие гидрохлорид венлафаксина
RU2401110C2 (ru) Препарат в форме пеллет с замедленным высвобождением для вертиго
MXPA05008711A (es) Uso de r-10-hidroxi-10,11-dihidro-carbamazepina en dolor neuropatico.
RU2015128915A (ru) Составы лоразепама с замедленным высвобождением